Ultragenyx Pharmaceutical Inc. – Contract (December 12th, 2016)
Ultragenyx Pharmaceutical Inc. – Contract (August 9th, 2016)
Contract (March 14th, 2008)
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
July 3, 2007 (July 10th, 2007)
This letter, upon your signature, will constitute the agreement between you and InterMune, Inc. (InterMune) regarding the terms of your separation from InterMune (the Separation Agreement) as a result of the 2007 reduction in force. This letter constitutes the final, binding terms of our agreement regarding your separation from employment.
AMENDMENT No. 6 to the License Agreement for Interferon Gamma (March 13th, 2006)
THIS AMENDMENT NUMBER SIX TO THE LICENSE AGREEMENT FOR INTERFERON GAMMA (Amendment) is entered into effective February 27, 2006 (the Amendment Effective Date), by and between Genentech, Inc. (Genentech) and InterMune, Inc. (InterMune). Genentech and InterMune may each be referred to herein as a Party and jointly as the Parties.
License Agreement (March 13th, 2006)
This LICENSE AGREEMENT (the Agreement) is made effective and entered into as of December 23, 2005 (the Effective Date), by and between InterMune, Inc. (Licensee), a corporation organized and existing under the laws of the State of Delaware, and Eli Lilly and Company (Lilly), a corporation organized and existing under the laws of the State of Indiana. Licensee and Lilly are sometimes referred to herein individually as a Party and collectively as Parties. For certain purposes under this Agreement, InterMune, Inc. is sometimes referred to as InterMune.
Asset Purchase Agreement (March 13th, 2006)
This Asset Purchase Agreement (this Agreement) is made and entered into as of December 23, 2005, by and between Targanta Therapeutics Corporation, a Delaware corporation (Buyer), and InterMune, Inc., a Delaware corporation (Seller).
Amendment Number 3 to Development and Supply Agreement Dated December 28, 2001 Between Abbott Laboratories and Intermune, Inc. (March 13th, 2006)
This Amendment No. 3, to the Development and Supply Agreement dated as of December 28, 2001, as amended by Amendment No. 1 dated April 26, 2002, Amendment No. 2 dated October 15, 2002, and the letter agreement regarding Authorization for Disclosure of Confidential Information dated July 18, 2003 (collectively, the Agreement), is effective as of December 22, 2005 (Amendment No. 3 Effective Date) between Abbott Laboratories, an Illinois corporation (Abbott), and InterMune, Inc., a Delaware corporation (InterMune). Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.
May 14, 2004 Thomas R. Kassberg [Address] (March 16th, 2005)
On behalf of InterMune, Inc., I am pleased to extend to you this official offer of employment with InterMune as Senior Vice President, Business Development, reporting to the Chief Executive Officer, beginning on August 2, 2004. Your position is a full-time position.
Amendment to Offer Letter Re Severance Pay and Change in Control (March 16th, 2005)
The following agreement (the Agreement) between InterMune, Inc. and Thomas R. Kassberg (Executive) is intended to amend the Offer Letter accepted by Executive on May 18, 2004 (the Offer Letter). Other than as specifically provided below, all terms and conditions of the Offer Letter continue in full force and effect.